PMC:6582309 / 58913-59501
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6582309","sourcedb":"PMC","sourceid":"6582309","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6582309","text":"Besides BACE1 and cholinesterase inhibitors several attempts have been made to develop immunotherapy treatments directed against Aβ or TAU (Bittar et al., 2018). A range of TAU-targeted immunotherapies have entered clinical development (recently reviewed in Novak et al., 2018). Clinical trials in patients with AD, which were administered Aβ peptide with conjugate to stimulate the immune response (i.e., active immunization) or anti-Aβ antibodies (i.e., passive immunization) have shown modest results and also serious side effects (reviewed in detail in Wisniewski and Drummond, 2016).","tracks":[{"project":"2_test","denotations":[{"id":"31249505-29507776-38601784","span":{"begin":155,"end":159},"obj":"29507776"},{"id":"31249505-30450030-38601785","span":{"begin":272,"end":276},"obj":"30450030"},{"id":"31249505-26577574-38601786","span":{"begin":582,"end":586},"obj":"26577574"}],"attributes":[{"subj":"31249505-29507776-38601784","pred":"source","obj":"2_test"},{"subj":"31249505-30450030-38601785","pred":"source","obj":"2_test"},{"subj":"31249505-26577574-38601786","pred":"source","obj":"2_test"}]},{"project":"0_colil","denotations":[{"id":"31249505-29507776-737209","span":{"begin":155,"end":159},"obj":"29507776"},{"id":"31249505-30450030-737210","span":{"begin":272,"end":276},"obj":"30450030"},{"id":"31249505-26577574-737211","span":{"begin":582,"end":586},"obj":"26577574"}],"attributes":[{"subj":"31249505-29507776-737209","pred":"source","obj":"0_colil"},{"subj":"31249505-30450030-737210","pred":"source","obj":"0_colil"},{"subj":"31249505-26577574-737211","pred":"source","obj":"0_colil"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ebec","default":true},{"id":"0_colil","color":"#ecd293"}]}]}}